Rapid and large-scale implementation of HCV treatment advances in France, 2007–2015

BMC Infectious Diseases

Table 1 Demographical characteristics of patients initiating HCV treatment by year of initiation and type of therapy, France, 2007–2015

Year	PEG-IFN/RBV bitherapy				1st- wave protease inhibitors				2nd- wave direct-acting antivirals				Total^b
	n	% men	Mean age (SD)		n	% men	Mean age (SD)		n	% men	Mean age (SD)		n	% men	Mean age (SD)
	n	% men	Men	Women	n	% men	Men	Women	n	% men	Men	Women	n	% men	Men	Women
2007	12,255	64.0	47.0 (10.4)	52.4 (12.8)	0	–	–	–	0	–	–	–	12,255	64.0	47.0 (10.4)	52.4 (12.8)
2008	11,317	65.3	47.1 (10.0)	52.1 (12.4)	0	–	–	–	0	–	–	–	11,317	65.3	47.1 (10.0)	52.1 (12.4)
2009	11,332	66.2	47.6 (9.9)	52.8 (12.1)	0	–	–	–	0	–	–	–	11,332	66.2	47.6 (9.9)	52.8 (12.1)
2010	9935	66.7	47.8 (10.2)	52.6 (12.0)	0	–	–	–	0	–	–	–	9935	66.7	47.8 (10.2)	52.6 (12.0)
2011	9565	67.1	48.2 (10.4)	54.1 (12.0)	1265	68.1	52.8 (9.0)	56.5 (10.3)	0	–	–	–	10,325	67.2	48.6 (10.4)	54.3 (11.9)
2012	7821	68.8	48.7 (10.7)	54.3 (12.5)	6037	65.4	51.9 (9.3)	57.3 (11.0)	0	–	–	–	12,488	67.4	49.9 (10.4)	55.6 (12.0)
2013	5640	71.8	47.7 (11.0)	54.5 (12.3)	3199	67.7	51.5 (9.6)	56.0 (11.6)	40	c	c	c	8382	70.5	48.9 (10.7)	55.2 (12.0)
2014	2969	74.8	47.9 (11.3)	55.0 (12.3)	474	70.9	50.1 (9.7)	53.4 (12.3)	8702	65.9	55.3 (9.2)	62.3 (10.9)	11,630	68.0	53.1 (10.5)	60.7 (11.7)
2015	536	83.4	38.7 (11.5)	49.1 (13.4)	35	c	c	c	14,650	64.4	54.9 (10.0)	62.1 (11.9)	15,189	65.1	54.2 (10.7)	61.9 (12.0)
Total^a	53,794	66.4	47.1 (10.5)	52.7 (12.5)	10,260	66.5	51.8 (9.4)	56.7 (11.2)	22,565	64.8	55.1 (9.8)	62.2 (11.6)	72,277	65.6	48.9 (11.0)	55.0 (13.0)

PEG-IFN Pegylated Interferon α, RBV Ribavirin, SD standard deviation
^aThe total for the 2007–2015 period is less than the sum of the annual numbers of patients because some patients may have initiated successive HCV treatments during the period. The total number of patients initiating a treatment (n = 72,277) during the 2007–2015 period is less than the sum of numbers of patients by type of therapy because some patients may have initiated successive HCV treatments with different types of therapies during the period
^bThe annual number of patients initiating a treatment was less than the sum of the annual numbers of patients by type of therapy because some patients may have initiated successive HCV treatments with different types of therapies during the same year
^cData not available because of small numbers

ISSN: 1471-2334